

# PGP9.5 Antibody

Rabbit mAb

Catalog # AP91153

## Product Information

<b>Application</b>	WB, IHC, IF, FC, ICC, IP, IHF
<b>Primary Accession</b>	<a href="#">P09936</a>
<b>Reactivity</b>	Rat, Human, Mouse
<b>Clonality</b>	Monoclonal
<b>Other Names</b>	HEL 117; NDGOA; Neuron cytoplasmic protein 9.5; PARK5; PGP9.5; Protein gene product 9.5; UCHL1;
<b>Isotype</b>	Rabbit IgG
<b>Host</b>	Rabbit
<b>Calculated MW</b>	24824

## Additional Information

<b>Dilution</b>	WB 1:500~1:2000 IHC 1:50~1:200 ICC/IF 1:50~1:200 IP 1:50 FC 1:50
<b>Purification</b>	Affinity-chromatography
<b>Immunogen</b>	A synthesized peptide derived from human PGP9.5
<b>Description</b>	Ubiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and may prevent its degradation in lysosomes. The homodimer may have ATP-independent ubiquitin ligase activity.
<b>Storage Condition and Buffer</b>	Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle.

## Protein Information

<b>Name</b>	UCHL1
<b>Function</b>	Deubiquitinase that plays a role in the regulation of several processes such as maintenance of synaptic function, cardiac function, inflammatory response or osteoclastogenesis (PubMed: <a href="#">22212137</a> , PubMed: <a href="#">23359680</a> ). Abrogates the ubiquitination of multiple proteins including WWTR1/TAZ, EGFR, HIF1A and beta-site amyloid precursor protein cleaving enzyme 1/BACE1 (PubMed: <a href="#">22212137</a> , PubMed: <a href="#">25615526</a> ). In addition, recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin to maintain a stable pool of monoubiquitin that is a key requirement for the ubiquitin-proteasome and the autophagy- lysosome pathways (PubMed: <a href="#">12408865</a> , PubMed: <a href="#">8639624</a> , PubMed: <a href="#">9774100</a> ). Regulates amyloid precursor protein/APP processing by promoting BACE1 degradation resulting in decreased amyloid beta production (PubMed: <a href="#">22212137</a> ). Plays a role in the

immune response by regulating the ability of MHC I molecules to reach cross-presentation compartments competent for generating Ag-MHC I complexes (By similarity). Mediates the 'Lys-48'-linked deubiquitination of the transcriptional coactivator WWTR1/TAZ leading to its stabilization and inhibition of osteoclastogenesis (By similarity). Deubiquitinates and stabilizes epidermal growth factor receptor EGFR to prevent its degradation and to activate its downstream mediators (By similarity). Modulates oxidative activity in skeletal muscle by regulating key mitochondrial oxidative proteins (By similarity). Enhances the activity of hypoxia-inducible factor 1-alpha/HIF1A by abrogating its VHL E3 ligase-mediated ubiquitination and consequently inhibiting its degradation (PubMed:[25615526](#)).


### Cellular Location

Cytoplasm. Endoplasmic reticulum membrane; Lipid- anchor. Note=About 30% of total UCHL1 is associated with membranes in brain. Localizes near and/or within mitochondria to potentially interact with mitochondrial proteins {ECO:0000250|UniProtKB:Q9R0P9}

### Tissue Location

Found in neuronal cell bodies and processes throughout the neocortex (at protein level). Expressed in neurons and cells of the diffuse neuroendocrine system and their tumors. Weakly expressed in ovary. Down-regulated in brains from Parkinson disease and Alzheimer disease patients.

## Images



Western blot analysis of PGP9.5 expression in 293T cell lysate.

Image not found : 202311/AP91153-IHC.jpg

Immunohistochemical analysis of paraffin-embedded human prostate cancer, using PGP9.5 Antibody.

Image not found : 202311/AP91153-IF.jpg

Immunofluorescent analysis of U87-MG cells, using PGP9.5 Antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.